Skip to main content
Erschienen in:

07.04.2020 | Melanoma

Near Infrared (NIR) Fluorescence is Not a Substitute for Lymphoscintigraphy and Gamma Probe for Melanoma Sentinel Node Detection: Results from a Prospective Trial

verfasst von: Carlos Eduardo Barbosa de Carvalho, M.D., Renato Capuzzo, M.D., MSc., Camila Crovador, RN, MSc., Renan J. Teixeira, PT, Ana Carolina Laus, Ph.D, Andre Lopes Carvalho, M.D., Ph.D, Vinicius L. Vazquez, M.D., Ph.D

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Sentinel lymph node (SLN) biopsy is the standard care for early detection and staging of lymph node metastasis in melanomas. Radiocolloids (RC) and blue dyes are used for SLN detection. Recently, near infrared (NIR) fluorescence tracing using indocyanine green has been developed as an alternative method for SLN detection. The relatively high tissue penetration depth of several millimeters and the ability to detect low concentrations of tracer both suggest that NIR may have significant advantages over RC and the blue dye methods. The objective of this study was to prospectively compare the performance of all three SLN detection techniques using them sequentially to evaluate the same group of patients.

Methods

One hundred twenty-one primary cutaneous melanoma patients with an indication for SLN biopsy were assigned to the procedure following NIR, blue dye, and RC detection techniques.

Results

No adverse event was reported. SLN was not detected in only 4.1% of cases. In 90.9%, an SLN was identified with NIR, but without any auxiliary technique in only 70.2% of cases. RC detected the SLN in 92.6% of cases. Patent blue was found in the sentinel node in 76.9%. The combination of all three techniques detected an SLN in 95.9% of cases. Metastases were present in 26.7%. The false-negative rate was 8.8%, with a negative predictive value of 91.2%.

Conclusions

RC was the only technique with high SLN detection. Both the blue dye and NIR methods added sensitivity to the detection rate but should not be a substitute for RC.
Literatur
1.
Zurück zum Zitat Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73. Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73.
2.
Zurück zum Zitat Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433–51. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433–51.
3.
Zurück zum Zitat van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann. Surg. 2008;248(6):949–55.CrossRef van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann. Surg. 2008;248(6):949–55.CrossRef
4.
Zurück zum Zitat Madu MF, Franke V, Van De Wiel B, et al. External validation of the 8th edition melanoma staging system of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. In: American Society of Clinical Oncology; 2018. Madu MF, Franke V, Van De Wiel B, et al. External validation of the 8th edition melanoma staging system of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. In: American Society of Clinical Oncology; 2018.
5.
Zurück zum Zitat Namikawa K, Aung PP, Milton DR, et al. Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma. Clin Cancer Res. 2019. Namikawa K, Aung PP, Milton DR, et al. Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma. Clin Cancer Res. 2019.
6.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRef Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.CrossRef
7.
Zurück zum Zitat Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230(4):453–463 (discussion 455–463). Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230(4):453–463 (discussion 455–463).
8.
Zurück zum Zitat Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976–83.CrossRef Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976–83.CrossRef
9.
Zurück zum Zitat Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7(6):469–74.CrossRef Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7(6):469–74.CrossRef
10.
Zurück zum Zitat van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol. 2013;168(1):93–8.CrossRef van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol. 2013;168(1):93–8.CrossRef
11.
Zurück zum Zitat Gilmore DM, Khullar OV, Gioux S, et al. Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol. 2013;20(7):2357–63.CrossRef Gilmore DM, Khullar OV, Gioux S, et al. Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol. 2013;20(7):2357–63.CrossRef
12.
Zurück zum Zitat Hope-Ross M, Yannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. Ophthalmology. 1994;101(3):529–33.CrossRef Hope-Ross M, Yannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. Ophthalmology. 1994;101(3):529–33.CrossRef
13.
Zurück zum Zitat Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F. Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol. 2012;106(1):41–5.CrossRef Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F. Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol. 2012;106(1):41–5.CrossRef
14.
Zurück zum Zitat Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: current controversies addressed. Eur J Surg Oncol. 2017;43(3):517–33.CrossRef Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: current controversies addressed. Eur J Surg Oncol. 2017;43(3):517–33.CrossRef
15.
Zurück zum Zitat Niebling MG, Pleijhuis RG, Bastiaannet E, Brouwers AH, van Dam GM, Hoekstra HJ. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016;42(4):466–73.CrossRef Niebling MG, Pleijhuis RG, Bastiaannet E, Brouwers AH, van Dam GM, Hoekstra HJ. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016;42(4):466–73.CrossRef
16.
Zurück zum Zitat Koonce S, Newman M. A systematic review of concordance between indocyanine green and 99 m technetium sentinel lymph node identification in melanoma. Clin Oncol. 2017;2:1308. Koonce S, Newman M. A systematic review of concordance between indocyanine green and 99 m technetium sentinel lymph node identification in melanoma. Clin Oncol. 2017;2:1308.
17.
Zurück zum Zitat Knackstedt R, Couto RA, Ko J, Cakmakoglu C, Wu D, Gastman B. Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in melanoma: increasing the sentinel lymph node-positive rate. Ann Surg Oncol. 2019;26(11):3550–60.CrossRef Knackstedt R, Couto RA, Ko J, Cakmakoglu C, Wu D, Gastman B. Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in melanoma: increasing the sentinel lymph node-positive rate. Ann Surg Oncol. 2019;26(11):3550–60.CrossRef
18.
Zurück zum Zitat Pameijer CR, Leung A, Neves RI, Zhu J. Indocyanine green and fluorescence lymphangiography for sentinel node identification in patients with melanoma. Am J Surg. 2018;216(3):558–61.CrossRef Pameijer CR, Leung A, Neves RI, Zhu J. Indocyanine green and fluorescence lymphangiography for sentinel node identification in patients with melanoma. Am J Surg. 2018;216(3):558–61.CrossRef
19.
Zurück zum Zitat Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.CrossRef Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.CrossRef
20.
Zurück zum Zitat de Lima Vazquez V, Silva TB, de Andrade Vieira M, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8(1):4.CrossRef de Lima Vazquez V, Silva TB, de Andrade Vieira M, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8(1):4.CrossRef
21.
Zurück zum Zitat da Costa LMM, de Souza Crovador C, de Carvalho CEB, de Lima Vazquez V. Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Res Notes. 2019;12(1):296.CrossRef da Costa LMM, de Souza Crovador C, de Carvalho CEB, de Lima Vazquez V. Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Res Notes. 2019;12(1):296.CrossRef
22.
Zurück zum Zitat Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(12):1655–63.CrossRef Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(12):1655–63.CrossRef
23.
Zurück zum Zitat Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9):2662.CrossRef Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9):2662.CrossRef
24.
Zurück zum Zitat Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378–86.PubMed Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378–86.PubMed
25.
Zurück zum Zitat Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17(3):709–17.CrossRef Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17(3):709–17.CrossRef
26.
Zurück zum Zitat Kretschmer L, Bertsch HP, Zapf A, et al. Nodal basin recurrence after sentinel lymph node biopsy for melanoma: a retrospective multicenter study in 2653 patients. Medicine. 2015;94(36). Kretschmer L, Bertsch HP, Zapf A, et al. Nodal basin recurrence after sentinel lymph node biopsy for melanoma: a retrospective multicenter study in 2653 patients. Medicine. 2015;94(36).
27.
Zurück zum Zitat Tejera-Vaquerizo A, Ribero S, Puig S, et al. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study. Cancer Med. 2019. Tejera-Vaquerizo A, Ribero S, Puig S, et al. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study. Cancer Med. 2019.
Metadaten
Titel
Near Infrared (NIR) Fluorescence is Not a Substitute for Lymphoscintigraphy and Gamma Probe for Melanoma Sentinel Node Detection: Results from a Prospective Trial
verfasst von
Carlos Eduardo Barbosa de Carvalho, M.D.
Renato Capuzzo, M.D., MSc.
Camila Crovador, RN, MSc.
Renan J. Teixeira, PT
Ana Carolina Laus, Ph.D
Andre Lopes Carvalho, M.D., Ph.D
Vinicius L. Vazquez, M.D., Ph.D
Publikationsdatum
07.04.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08409-6

Neu im Fachgebiet Chirurgie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Appendizitis und Darminfarkt durch Blinddarm-Lipom

Eigentlich sind Lipome recht harmlos. Im Zäkum können sie jedoch erhebliche Komplikationen mit Darminfarkt und Appendizitis verursachen.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

MedTalk Leitlinie KOMPAKT: S3-Leitline zu peripheren Nervenverletzungen

  • Webinar | 10.02.2025 | 13:00

Über den Weg zur finalen Fassung der S3-Leitlinie "Versorgung peripherer Nervenverletzungen" sprechen Prof. Dr. Leila Harhaus-Wähner und Ressortleiter Dr. Gunter Freese im WebTalk Leitlinie KOMPAKT, einer neuen Webcast-Serie von SpringerMedizin passend zu Ihrem Fachmagazin Orthopädie und Unfallchirurgie Mitteilungen und Nachrichten. In dem kurzen Video geht es darum, was sich im Vergleich zur vorigen Fassung der Leitlinie geändert hat, welche Aspekte für die tägliche Praxis besonders wichtig sind und was jeder gemäß Leitlinie nun anders oder besser machen sollte.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.